S&P 500   4,981.80
DOW   38,612.24
QQQ   425.61
Palo Alto Networks, Keysight fall; Garmin, Toll Brothers rise, Wednesday, 2/21/2024
Gold Could Be Heading for Record Highs - But How to Play It? (Ad)
Palo Alto Networks aims at cyber security leadership
3 Reasons the Capital One-Discover merger is a big deal
Is Gold Really Boring? (Ad)
How major US stock indexes fared Wednesday, 2/21/2024
Germany says Europe's largest economy is in 'troubled waters' and cuts its growth forecast
Is Gold Really Boring? (Ad)
Teladoc Health gaps down to support level after weak guidance
Housing data weakens, but Toll Brothers stock is still a buy
S&P 500   4,981.80
DOW   38,612.24
QQQ   425.61
Palo Alto Networks, Keysight fall; Garmin, Toll Brothers rise, Wednesday, 2/21/2024
Gold Could Be Heading for Record Highs - But How to Play It? (Ad)
Palo Alto Networks aims at cyber security leadership
3 Reasons the Capital One-Discover merger is a big deal
Is Gold Really Boring? (Ad)
How major US stock indexes fared Wednesday, 2/21/2024
Germany says Europe's largest economy is in 'troubled waters' and cuts its growth forecast
Is Gold Really Boring? (Ad)
Teladoc Health gaps down to support level after weak guidance
Housing data weakens, but Toll Brothers stock is still a buy
S&P 500   4,981.80
DOW   38,612.24
QQQ   425.61
Palo Alto Networks, Keysight fall; Garmin, Toll Brothers rise, Wednesday, 2/21/2024
Gold Could Be Heading for Record Highs - But How to Play It? (Ad)
Palo Alto Networks aims at cyber security leadership
3 Reasons the Capital One-Discover merger is a big deal
Is Gold Really Boring? (Ad)
How major US stock indexes fared Wednesday, 2/21/2024
Germany says Europe's largest economy is in 'troubled waters' and cuts its growth forecast
Is Gold Really Boring? (Ad)
Teladoc Health gaps down to support level after weak guidance
Housing data weakens, but Toll Brothers stock is still a buy
S&P 500   4,981.80
DOW   38,612.24
QQQ   425.61
Palo Alto Networks, Keysight fall; Garmin, Toll Brothers rise, Wednesday, 2/21/2024
Gold Could Be Heading for Record Highs - But How to Play It? (Ad)
Palo Alto Networks aims at cyber security leadership
3 Reasons the Capital One-Discover merger is a big deal
Is Gold Really Boring? (Ad)
How major US stock indexes fared Wednesday, 2/21/2024
Germany says Europe's largest economy is in 'troubled waters' and cuts its growth forecast
Is Gold Really Boring? (Ad)
Teladoc Health gaps down to support level after weak guidance
Housing data weakens, but Toll Brothers stock is still a buy
NASDAQ:BCPC

Balchem (BCPC) Stock Price, News & Analysis

$153.66
-3.61 (-2.30%)
(As of 02/21/2024 ET)
Today's Range
$152.34
$155.91
50-Day Range
$137.06
$157.27
52-Week Range
$110.74
$157.46
Volume
190,061 shs
Average Volume
105,544 shs
Market Capitalization
$4.96 billion
P/E Ratio
45.87
Dividend Yield
0.51%
Price Target
$135.00

Balchem MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
12.1% Downside
$135.00 Price Target
Short Interest
Healthy
0.86% of Float Sold Short
Dividend Strength
Strong
Based on Four Factors
Sustainability
-1.54
Upright™ Environmental Score
News Sentiment
0.92mentions of Balchem in the last 14 days
Based on 24 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
5.05%
From $3.76 to $3.95 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.95 out of 5 stars

Basic Materials Sector

53rd out of 170 stocks

Chemicals & Allied Products Industry

5th out of 16 stocks


BCPC stock logo

About Balchem Stock (NASDAQ:BCPC)

Balchem Corporation develops, manufactures, and markets specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition, and industrial markets in the United States and internationally. It operates through three segments: Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products. The Human Nutrition & Health segment supplies ingredients in the food and beverage industry. Its products include spray dried and emulsified powders, extrusion and agglomeration, blended lipid systems, liquid flavor delivery systems, juice and dairy bases, chocolate systems, and cereal systems, as well as ice cream bases and variegates. This segment also offers microencapsulation solutions for various applications; and human grade choline nutrients and mineral amino acid chelated products for nutrition and health applications. The Animal Nutrition & Health segment provides microencapsulated products to enhance health and milk production, and delivering nutrient supplements in ruminant animals; chelation technology, which offers enhanced nutrient absorption for various species of production and companion animals; and choline chloride, a nutrient for monogastric animal health. The Specialty Products segment offers ethylene oxide primarily for use in the health care industry; single use canisters for sterilizing re-usable devices; and ammonia. This segment also markets and sells propylene oxide, a fumigant to aid in the control of insects and microbiological spoilage, as well as to reduce bacterial and mold contamination in shell and processed nut meats, processed spices, cacao beans, cocoa powder, raisins, figs, and prunes; and chelated minerals for high value crops. The company sells its products through sales force, independent distributors, and sales agents. Balchem Corporation was incorporated in 1967 and is headquartered in Montvale, New Jersey.

BCPC Stock Price History

BCPC Stock News Headlines

Balchem (NASDAQ:BCPC) Upgraded to "Buy" at StockNews.com
Gold Could Be Heading for Record Highs - But How to Play It?
According to FX Empire, the gold forecast is now bullish, with support for a $3,000 target in 2024. The big question is how to play it. Some investors are discovering a unique gold investment alternative that sidesteps the major issues with gold mining stocks or physical gold.
Balchem: Potential Turnaround Is In The Price
BCPC Mar 2024 150.000 call
Balchem Full Year 2023 Earnings: EPS Misses Expectations
BCPC Mar 2024 175.000 call
Gold Could Be Heading for Record Highs - But How to Play It?
According to FX Empire, the gold forecast is now bullish, with support for a $3,000 target in 2024. The big question is how to play it. Some investors are discovering a unique gold investment alternative that sidesteps the major issues with gold mining stocks or physical gold.
Balchem (NASDAQ:BCPC) Hits New 12-Month High After Strong Earnings
BCPC Mar 2024 145.000 call
Balchem Q4 2023 Earnings Preview
Balchem (BCPC) Set to Announce Quarterly Earnings on Friday
Balchem Corp BCPC
Balchem Q3: A Solid Performer Is Seeing A Soft 2023
See More Headlines
Receive BCPC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Balchem and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Ex-Dividend for 1/19 Dividend
12/26/2023
Ex-Dividend for 1/16 Dividend
12/28/2023
Dividend Payable
1/16/2024
Dividend Payable
1/19/2024
Last Earnings
2/16/2024
Today
2/22/2024
Next Earnings (Estimated)
4/26/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Industry
Chemicals & allied products
Sub-Industry
Specialty Chemicals
Current Symbol
NASDAQ:BCPC
CUSIP
05766520
CIK
9326
Employees
1,340
Year Founded
1967

Price Target and Rating

Average Stock Price Target
$135.00
High Stock Price Target
$135.00
Low Stock Price Target
$135.00
Potential Upside/Downside
-12.1%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$108.54 million
Pretax Margin
14.88%

Debt

Sales & Book Value

Annual Sales
$922.44 million
Cash Flow
$5.22 per share
Book Value
$32.69 per share

Miscellaneous

Free Float
31,670,000
Market Cap
$4.95 billion
Optionable
Optionable
Beta
0.70

Social Links

Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.

Get This Free Report

Key Executives

  • Mr. Theodore L. Harris (Age 59)
    Chairman, CEO & President
    Comp: $2.33M
  • Mr. Carl Martin Bengtsson (Age 46)
    Executive VP, CFO & Treasurer
    Comp: $864.13k
  • Ms. Hatsuki Miyata (Age 48)
    Executive VP, General Counsel & Secretary
    Comp: $618.21k
  • Mr. Jonathan H. Griffin (Age 48)
    Senior VP and GM of Animal Nutrition & Health
    Comp: $624.01k
  • Mr. Martin Luther Reid (Age 56)
    Senior VP & Chief Supply Chain Officer
    Comp: $672.26k
  • Mr. William A. Backus CPA (Age 58)
    VP & CAO
    Comp: $560.79k
  • Mr. Michael R. Sestrick Ph.D. (Age 60)
    Senior VP & CTO
  • Mr. Brent Tignor (Age 46)
    Senior VP & Chief Human Resources Officer
  • Mr. Frederic Boned (Age 46)
    Senior VP and GM of Human Nutrition & Health
  • Mr. Job L. van Gunsteren (Age 48)
    Senior VP & GM of Specialty Products














BCPC Stock Analysis - Frequently Asked Questions

Should I buy or sell Balchem stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Balchem in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" BCPC shares.
View BCPC analyst ratings
or view top-rated stocks.

What is Balchem's stock price target for 2024?

1 Wall Street research analysts have issued twelve-month price targets for Balchem's stock. Their BCPC share price targets range from $135.00 to $135.00. On average, they predict the company's stock price to reach $135.00 in the next twelve months. This suggests that the stock has a possible downside of 12.1%.
View analysts price targets for BCPC
or view top-rated stocks among Wall Street analysts.

How have BCPC shares performed in 2024?

Balchem's stock was trading at $148.75 at the beginning of the year. Since then, BCPC stock has increased by 3.3% and is now trading at $153.66.
View the best growth stocks for 2024 here
.

When is Balchem's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, April 26th 2024.
View our BCPC earnings forecast
.

How were Balchem's earnings last quarter?

Balchem Co. (NASDAQ:BCPC) issued its quarterly earnings data on Friday, February, 16th. The basic materials company reported $0.95 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.93 by $0.02. The basic materials company earned $228.70 million during the quarter, compared to analysts' expectations of $234.66 million. Balchem had a net margin of 11.77% and a trailing twelve-month return on equity of 10.69%. Balchem's quarterly revenue was down 1.6% compared to the same quarter last year. During the same quarter last year, the business earned $0.66 EPS.

How often does Balchem pay dividends? What is the dividend yield for Balchem?

Balchem declared an annual dividend on Monday, December 4th. Investors of record on Wednesday, December 27th will be given a dividend of $0.79 per share on Friday, January 19th. This represents a dividend yield of 0.6%. The ex-dividend date is Tuesday, December 26th. This is an increase from the stock's previous annual dividend of $0.40.
Read our dividend analysis for BCPC
.

Is Balchem a good dividend stock?

Balchem (NASDAQ:BCPC) pays an annual dividend of $0.79 per share and currently has a dividend yield of 0.50%. The company has been increasing its dividend for 15 consecutive years, indicating the company has a strong committment to maintain and grow its dividend. The dividend payout ratio is 23.58%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, BCPC will have a dividend payout ratio of 20.00% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for BCPC.

What is Dino A. Rossi's approval rating as Balchem's CEO?

25 employees have rated Balchem Chief Executive Officer Dino A. Rossi on Glassdoor.com. Dino A. Rossi has an approval rating of 85% among the company's employees. 62.0% of employees surveyed would recommend working at Balchem to a friend.

What other stocks do shareholders of Balchem own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Balchem investors own include Ecolab (ECL), CVS Health (CVS), AbbVie (ABBV), Johnson & Johnson (JNJ), Lowe's Companies (LOW), Altria Group (MO), NVIDIA (NVDA), AT&T (T), Analog Devices (ADI) and Bristol-Myers Squibb (BMY).

Who are Balchem's major shareholders?

Balchem's stock is owned by a number of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (11.76%), Wasatch Advisors LP (5.93%), Conestoga Capital Advisors LLC (3.36%), Geneva Capital Management LLC (2.38%), Dimensional Fund Advisors LP (2.13%) and Clearbridge Investments LLC (1.62%). Insiders that own company stock include David B Fischer, Gunsteren Job Leonard Van, Michael Robert Sestrick and William A Backus.
View institutional ownership trends
.

How do I buy shares of Balchem?

Shares of BCPC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Does Balchem have any subsidiaries?
The following companies are subsidiares of Balchem: Aberco Inc., Aberco Inc., Albion Laboratories Inc., Albion Laboratories Inc., BCP Ingredients Inc., Balchem BV, Balchem Italia Srl, Balchem Ltd., Balchem NV, Balchem Pte Ltd., Balchem Pty Ltd., Balchem Sdn Bhd, Bioscreen technologies, Chemogas Holding NV, Chol-Mix Kft, Innovative Food Processors, SensoryEffects, SensoryEffects Cereal Systems Inc., SensoryEffects Inc., Stereo Gas Philippines Inc., and Zumbro River Brand Inc..
Read More
This page (NASDAQ:BCPC) was last updated on 2/22/2024 by MarketBeat.com Staff